Table 1 Haematological, cytogenetic, and molecular levels of remission of CML patients after 6-month monitoring period
Patient outcome | No. = 49 | |
|---|---|---|
CHR-CCR-CMR | 12 (24.5%) | |
CHR-CCR-MMR | 5 (10.2%) | |
CHR-CCR-NMR | 4 (8.2%) | |
CHR-MCR-CMR | 2 (4.1%) | |
CHR-MCR-MMR | 1 (2.0%) | |
CHR-MCR-NMR | 7 (14.3%) | |
CHR-NCR-NMR | 9 (18.4%) | |
NHR-CCR-MMR | 1 (2.0%) | |
NHR-MCR-NMR | 2 (4.1%) | |
NHR-NCR-NMR | 6 (12.2%) | |
Outcome; molecular remission | NMR | 28 (57.1%) |
MMR | 7 (14.3%) | |
CMR | 14 (28.6%) | |